Back to top
more

Dentsply Sirona (XRAY)

(Delayed Data from NSDQ)

$26.09 USD

26.09
1,073,045

-0.08 (-0.31%)

Updated Sep 24, 2024 04:00 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value B Growth B Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 32% (172 out of 252)

Industry: Medical - Dental Supplies

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Is a Beat Likely for DENTSPLY SIRONA (XRAY) in Q3 Earnings?

by Zacks Equity Research

DENTSPLY SIRONA's (XRAY) third-quarter 2023 results are likely to reflect a recovery in demand for consumable products, partially offset by lower sales in China due to volume-based procurement policy.

Cardinal Health (CAH) Reports Next Week: Wall Street Expects Earnings Growth

by Zacks Equity Research

Cardinal (CAH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Hologic (HOLX) to Report Q4 Earnings: What's in the Cards?

by Zacks Equity Research

Strength in Breast Health and GYN Surgical businesses will likely drive Hologic's (HOLX) Q4 revenues.

McKesson (MCK) to Report Q2 Earnings: What's in the Cards?

by Zacks Equity Research

McKesson's (MCK) second-quarter fiscal 2024 results are likely to reflect the solid display by the U.S. Pharmaceutical and Specialty Solutions segment.

Merit Medical (MMSI) Beats Q3 Earnings and Revenue Estimates

by Zacks Equity Research

Merit Medical (MMSI) delivered earnings and revenue surprises of 15.38% and 2.93%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?

Ecolab (ECL) to Report Q3 Earnings: What's in the Offing?

by Zacks Equity Research

Ecolab's (ECL) third-quarter results are likely to reflect continued segmental strength.

Revvity (RVTY) to Report Q3 Earnings: What's in the Cards?

by Zacks Equity Research

Revvity's (RVTY) third-quarter results are likely to reflect weak performance at the Diagnostics segment, partially offset by strong demand for Life Sciences and Diagnostics franchise.

Dentsply International (XRAY) Reports Next Week: Wall Street Expects Earnings Growth

by Zacks Equity Research

Dentsply (XRAY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

What's in Store for Canopy Growth (CGC) in Q2 Earnings?

by Zacks Equity Research

In the second quarter of fiscal 2024, Canopy Growth (CGS) is expected to demonstrate an improved performance in the Canadian cannabis business.

DexCom (DXCM) to Report Q3 Earnings: Is a Beat in Store?

by Zacks Equity Research

DexCom's (DXCM) third-quarter 2023 results are likely to reflect rising volumes across all channels.

InMode (INMD) to Post Q3 Earnings: What's in the Cards?

by Zacks Equity Research

InMode (INMD) is likely to register growth in Q3, backed by strong consumable and service revenues and ongoing global expansion.

CVS Health (CVS) to Report Q3 Earnings: What's in the Cards?

by Zacks Equity Research

CVS Health (CVS) Q3 revenues will likely benefit from growth in specialty pharmacy and brand inflation and increased prescription and front store volume.

Will the Medicare Unit Aid Molina Healthcare's (MOH) Q3 Earnings?

by Zacks Equity Research

Molina Healthcare's (MOH) Q3 results are expected to benefit on growing premiums and an expanding customer base within its Medicaid and Medicare businesses, partly offset by increased medical costs.

Labcorp (LH) to Report Q3 Earnings: What's in the Cards?

by Zacks Equity Research

Labcorp's (LH) third-quarter 2023 performance is likely to have witnessed strength in the Diagnostics Laboratories base business.

IDEXX Laboratories (IDXX) to Post Q3 Earnings: What's in Store?

by Zacks Equity Research

IDEXX Laboratories' (IDXX) third-quarter 2023 results are expected to reflect an impressive performance of the CAG segment.

What's in Store for Option Care Health (OPCH) in Q3 Earnings?

by Zacks Equity Research

Option Care Health's (OPCH) Q3 results are likely to be driven by sustained strong utilization.

Will Patient Volumes Aid Community Health's (CYH) Q3 Earnings?

by Zacks Equity Research

Community Health's (CYH) third-quarter results are likely to benefit from improved payer mix and growing surgery volumes, partly offset by a decline in patient days.

Elevance Health (ELV) Q3 Earnings Beat on Carelon Unit Strength

by Zacks Equity Research

Membership growth in the Medicare Advantage business and strong segmental performance aid Elevance Health's (ELV) Q3 results. An encouraging 2023 earnings guidance also bodes well for investors.

XRAY or COO: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

XRAY vs. COO: Which Stock Is the Better Value Option?

Reasons to Retain DENTSPLY SIRONA (XRAY) in Your Portfolio

by Zacks Equity Research

DENTSPLY SIRONA (XRAY) continues to gain traction from a robust product portfolio. However, macroeconomic factors like weakened global demand, rising costs and forex woes persist.

Reasons to Add The Cooper Companies (COO) to Your Portfolio

by Zacks Equity Research

The Cooper Companies (COO) continues to benefit from strength in its business segments. Its acquisitions are likely to drive the top line further.

DENTSPLY SIRONA (XRAY) Beats on Q2 Earnings, Ups '23 EPS View

by Zacks Equity Research

DENTSPLY SIRONA's (XRAY) Q2 revenues are driven by a rise in demand across key markets, especially in China. Improved pricing and restructuring initiatives boost earnings.

Is a Beat Likely for DENTSPLY SIRONA (XRAY) in Q2 Earnings?

by Zacks Equity Research

DENTSPLY SIRONA's (XRAY) second-quarter 2023 results are likely to reflect recovery in demand for consumable products, partially offset by lower sales in China due to volume-based procurement policy.

Charles River (CRL) to Report Q2 Earnings: What's in Store?

by Zacks Equity Research

Continued global demand for research models and associated services' strong DSA segment performance is likely to have driven Charles River's (CRL) Q2 revenues.

InMode (INMD) to Post Q2 Earnings: What's in the Cards?

by Zacks Equity Research

InMode (INMD) is expected to report strong Q2 consumable and service revenues, banking on strong performances of seven patented technologies across 10 product families.